Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter studyWILLASCH, A. M; GRUHN, B; BIONDI, A et al.Leukemia. 2009, Vol 23, Num 8, pp 1472-1479, issn 0887-6924, 8 p.Article

Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemiaHOELLE, W; BECK, J. F; DUECKERS, G et al.Bone marrow transplantation (Basingstoke). 2004, Vol 33, Num 2, pp 219-223, issn 0268-3369, 5 p.Article

Rezidivprophylaxe bei Kindern mit ALL-, AML- und MDS nach allogener Stammzelltransplantation durch interventionelle Immuntherapie im kritischen Stadium eines ansteigenden gemischten Chimärismus = Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerismBECK, J. F; KLINGEBIEL, T; KREYENBERG, H et al.Klinische Pädiatrie. 2002, Vol 214, Num 4, pp 201-205, issn 0300-8630Article

The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantationLION, T; WATZINGER, F; LAWLER, M et al.Leukemia. 2012, Vol 26, Num 8, pp 1821-1828, issn 0887-6924, 8 p.Article

How and when should we monitor chimerism after allogeneic stem cell transplantation?BADER, P; NIETHAMMER, D; WILLASCH, A et al.Bone marrow transplantation (Basingstoke). 2005, Vol 35, Num 2, pp 107-119, issn 0268-3369, 13 p.Article

Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experienceKREYENBERG, H; HÖLLE, W; MÖHRLE, S et al.Leukemia. 2003, Vol 17, Num 1, pp 237-240, issn 0887-6924, 4 p.Article

Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysisWILLASCH, A; EING, S; KREYENBERG, H et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 1, pp 181-189, issn 0268-3369, 9 p.Article

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantationWEBER, G; KARBACH, J; BADER, P et al.Leukemia. 2009, Vol 23, Num 9, pp 1634-1642, issn 0887-6924, 9 p.Article

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALLBADER, P; HANCOCK, J; KREYENBERG, H et al.Leukemia. 2002, Vol 16, Num 9, pp 1668-1672, issn 0887-6924Article

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemiaHANDGRETINGER, R; ZUGMAIER, G; HENZE, G et al.Leukemia. 2011, Vol 25, Num 1, pp 181-184, issn 0887-6924, 4 p.Article

Standardization of DNA isolation from low cell numbers for chimerism analysis by PCR of short tandem repeatsVAN DER BURG, M; KREYENBERG, H; DIAZ, M. G et al.Leukemia. 2011, Vol 25, Num 9, pp 1467-1470, issn 0887-6924, 4 p.Article

Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effectiveBADER, P; KREYENBERG, H; GRUHN, B et al.Bone marrow transplantation (Basingstoke). 2004, Vol 33, Num 8, pp 815-821, issn 0268-3369, 7 p.Article